Why Shares in Arrowhead Pharmaceuticals Surged on News of a Novartis Deal

Shares in Arrowhead Pharmaceuticals (NASDAQ: ARWR) rose by more than 27% in the week to Friday morning. The company's bold aim is to have "20 individual products, either partnered or wholly owned, in clinical trials or on the market by 2025," and the company moved a step closer to that aim with the signing of a global licensing and collaboration agreement with pharmaceutical giant Novartis for ARO-SNCA, a preclinical therapy targeting neurodegenerative diseases, including Parkinson's disease. As a result of the deal:For reference, the TRiM platform is a key part of the investment case for the stock. Arrowhead's therapies trigger ribonucleic acid (RNA) interference mechanisms. RNA carries out functions encoded in DNA, and in triggering RNA interference, a therapy can target a gene and "silence a disease." The TRiM platform is Arrowhead's proprietary system that enables it to create new RNAi therapies, based on targeted delivery of the therapy to multiple tissues in the body.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool